Top psych stories of January: Global impact of mental disorders, support for psychedelics

Healio’s most-viewed psychiatry stories in January highlight the global burden of mental disorders on health, a survey that provides insights into Americans’ support of psychedelics and a regulatory development for Rexulti.

Mental disorders remain significant global burden on health

The prevalence of mental disorders has been on the rise and remains a significant leading cause of disease burden worldwide, according to a 30-year global systematic analysis published in The Lancet Psychiatry. Read more.

Survey shows many Americans support psychedelics to treat mental health issues

Two-thirds of Americans with treatment-resistant anxiety, depression or PTSD believe that psychedelics should be made available for therapeutic means, according to U.S. adults who took part in a survey conducted by The Harris Poll. Read more.

FDA approves supplemental new drug application for Rexulti in pediatric patients

The FDA has approved the supplemental new drug application for Rexulti for treating schizophrenia in patients aged 13 to 17 years, Otsuka and Lundbeck announced. Read more.

CDC: Geographic, socioeconomic factors linked to suicidal behaviors in adults

Suicidal thoughts and behaviors in the U.S. adult population arise due to several factors, including geography, demographics, socioeconomic status and cultural setting, according to study findings published in MMWR. Read more.

Esmethadone effective for patients with major depressive disorder

Esmethadone produced fast and consistent positive outcomes in patients for whom previous treatments for depression were not effective, according to a randomized, double-blind study published in the American Journal of Psychiatry. Read more.